tbuckley/cabot-search huggingface dataset:
Abstract 16466: Impaired Function of Circulating CD34+/KDR+ Endothelial Progenitor Cells in Patients With Persistent Atrial Fibrillation is Restored by the Calcium Channel Blocker Bepridil Hydrochloride
Authors: Takeshi Wada, Youichi Katoh, Show Nagamine, Hiroyuki Isogai, Dai Ozaki, Hiroshige Yuu, Midori Kakihara, Masaaki Maki, Miki Yamase, Ken Yokoyma, Kenji Yaginuma, Tetsuya Oigawa, Koji Tokano, Yuji Nakazato
Journal: Circulation (2013)

Background: Despite accumulating evidence regarding the occurrence of endothelial dysfunction in chronic atrial fibrillation (AF) patients, little is still known about the number and function of ci...
Hepatic arterial infusion (HAI) of oxaliplatin combined with docetaxel and capecitabine in patients with liver metastases from non-colorectal gastrointestinal tumours: A dose-finding study
Authors: A. Hernandez, J. Rodriguez, A. Viudez, A. Chopitea, E. Bandres, R. Zarate, M. Ponz-Sarvise, C. Olier, C. Reyna, J. Garcia-Foncillas
Journal: Journal of Clinical Oncology (2008)

15666 Background: Different schedules of HAI-oxaliplatin have demonstrated preliminary evidence of activity in g.i. tumours. The aim of this study is to establish the maximun tolerated dose (MTD) and the recommended dose (RD) of HAI-oxaliplatin given every three weeks in combination with docetaxel and capecitabine in patients with liver metastases from non colorectal gastrointestinal tumours. Methods: Patients with hepatic metastases from gastroesophagic junction (n=2), gastric (n= 11), cholangiocarcinoma (n= 2) and pancreatic (n=6) tumours were included. Extrahepatic disease other than the primary tumour and prior chemotherapy for metastatic disease were considered exclusion criteria. Fixed doses of Docetaxel (60mg/m2 i.v. on day 1) and Capecitabine (650mg/m2 p.o. bid on days 1 to14) were administered every 3 weeks. HAI-oxaliplatin dose was escalated from 100mg/m2 IA in cohorts of 3 patients, with a 10-mg/m2 increase in each cohort. Results: 21patients (16M/5F, median age: 59, median ECOG: 1) were included. The median number of cycles administered was 5 (2–9). No dose limiting toxicity (DLT) was observed in cohort 1 (100 mg/m2) and 2 (110 mg/m2). 1 out of 3 pts at cohort 3 (120 mg/m2) developed grade 3 hyperbilirubinemia and cholangitis. Three more pts were included in this cohort, with no additional toxicity. DLT occurred in the three pts at the 130 mg/m2 dose level and consisted of grade 4 thrombocytopenia, grade 3 mucositis and grade 3 asthenia. Subsequently, 6 more patients were recruited at cohort 3, with no further DLT. Overall, main grade 3–4 toxicities were asthenia (9.6%), anaemia (9.5%), neutropenia (18.1%, including 2 pts with febrile neutropenia), mucositis (9.6%) and pain related to oxaliplatin infusion (28.6%). Other toxicities included grade 2 neurotoxicity (19%), grade 2 hand-foot syndrome (14.3%) and hepatic toxicity (6 pts with transient elevation of liver enzymes). Preliminary evidence of activity has been noted, with 15 pts achieving major radiological responses. Conclusions: The MTD of HAI-Oxaliplatin when combined with docetaxel and capecitabine is 120 mg/m2. No significant financial relationships to disclose.
Abstract 9920: Evaluation of Global Circumferential Strain as Prognostic Marker After Administration of {beta}-blockers for Dilated Cardiomyopathy
Authors: Hidekazu Tanaka, Yasuhide Mochizuki, Kensuke Matsumoto, Yoshiki Yamadori, Takuma Sawa, Yoshiki Motoji, Junichi Imanishi, Tatsuya Miyoshi, Yuko Fukuda, Kazuhiro Tatsumi, Tetsuari Onishi, Hiroya Kawai, Ken-ichi Hirata
Journal: Circulation (2013)

Background: The prognosis of dilated cardiomyopathy (DCM) has improved by the use of β-blockers, and the appearance of left ventricular (LV) reverse remodeling is generally thought to result in a f...
Needs and psychological distress in oncological inpatients with colorectal cancer
Authors: P. Heras, K. Kritikos, S. Karagiannis, P. Serenes, A. Argyriou, N. Kritikos
Journal: Journal of Clinical Oncology (2004)

8181 Background: The aim of this prospective study was to identify psychological distress and associated specific needs in newly diagnosed oncological pts with colorectal cancer and in pts previously treated or undergoing treatment with different modalities. Methods: From July 1998 to June 2003, 150 inpatients with colorectal cancer at the Division of Medical Oncology, General “Hippocrates” Hospital of Kos, were interviewed by means of self-administered questionnaires for the evaluation of needs (NEQ) and of anxiety and depression (HADS). Both newly diagnosed pts “new pts” and patients undergoing treatment for a maximum of 6 months “old pts”were evaluated. 92 patients were male and 58 were female. 76 patients were new patients and 74 patients were old. Median age was 56 years. 45% of patients have attended school for at least 6 years. This study assesses the needs of pts with HADS >14 as compared with to those with with HADS <,= 14. Results: The difference in the perception of needs does not seem to depend on the phase of the illness, old versus new, but on the presence of a psychological distress (HADS > 14), that has been detected in 50% of patients (old 48%, new 52%). The emerging needs in distressed versus non-distressed included respect of intimacy (OR=4.77), a greater reassurance by physicians (OR=4.05), not feeling neglected (OR=3.89), having greater control over physical disorders (OR=3.75), being able to talk to a priest (OR=4.73) and to a psychologist (OR=3.52). Needs such as having greater reassurance from relatives (OR=2.42), greater interaction with physicians (OR=2.04), more intelligible information (OR=2.29) and more information on prognosis (OR=1.91) are less clearly expressed. All OR were statistically significant. Conclusions: Data show that psychological distress remains for as long as 6 months after diagnosis of colorectal cancer and that these needs are felt mostly by patients with psychological distress. No significant financial relationships to disclose.
Chemoradiation therapy in patients (pts) with small cell lung cancer (SCLC) with pericardial effusion but no distant metastasis
Authors: S. Niho, K. Kubota, K. Yoh, K. Goto, H. Ohmatsu, N. Saijo, Y. Nishiwaki
Journal: Journal of Clinical Oncology (2009)

7555 Background: Our previous retrospective analysis demonstrated that the survival of the limited-disease (LD) SCLC pts with ipsilateral pleural effusion was intermediate between those of LD pts without ipsilateral pleural effusion and extensive-disease (ED) pts, and that long-term survival was achieved by LD-SCLC pts with ipsilateral pleural effusion who successfully underwent chemoradiotherapy (CRT) (J Thorac Oncol 2008;3:723–7). We retrospectively investigated the clinical course and outcome in pts with SCLC with pericardial effusion but no distant metastasis and examined the overall survival in pts who received chemotherapy and definitive thoracic radiotherapy (TRT). Methods: The medical records of SCLC pts who received treatment at the National Cancer Center Hospital East between July 1992 and December 2007 were reviewed. During this period 767 pts were newly diagnosed as having SCLC. Four-hundred seventeen pts had no distant metastasis. Ninety-six of those 417 pts (23%, 95% confidence interval (CI): 19–27%) had pleural or pericardial effusion or disseminated pleural nodules, and were included in this study. The 96 pts were divided into two groups: group A included pts with pericardial effusion (n=33), and group B included pts who had pleural effusion and/or disseminated pleural nodules, but did not have pericardial effusion (n=63). Sixteen pts had both pleural and pericardial effusion. Results: All but one patient received systemic chemotherapy. A remaining patient with pleural effusion received only best supportive care. In group A, 19 pts received chemoradiotherapy. TRT was conducted concurrently with 3 or 4 cycles of chemotherapy in 12 pts and sequentially in 7 pts. The response rate for first-line chemotherapy was 79%. In group B, 26 pts received chemoradiotherapy. Survival data were shown as below. Conclusions: Long-term survival was seldom achieved by SCLC pts with pericardial effusion but no distant metastasis, even if they underwent chemoradiotherapy. [Table: see text] No significant financial relationships to disclose.
Conversion of antibody-resistant cancer patients to antibody-sensitive: Investigation of Fc receptor polymorphisms and response to IL-2 and rituximab treatment in rituximab-refractory NHL patients
Authors: C. F. Eisenbeis, J. Leonard, J. Rosenblatt, K. D. Khan, P. Porcu, S. Milan, S. E. Wilson, D. Hurst, M. A. Caligiuri, L. Piro
Journal: Journal of Clinical Oncology (2004)

2534 Background: Antibody-dependent cellular cytotoxicty (ADCC) is an important mechanism of rituximab activity. Genetic polymorphisms in FcγRIIIa and FcγRIIa have been reported to influence response to rituximab in follicular non-Hodgkin's lymphoma (NHL) patients. Interleukin-2 (IL2, Proleukin) induces expansion and activation of FcR bearing cells, enhancing ADCC. Methods: We evaluated combination therapy with IL2 and rituximab (IL2+R) in low grade/follicular NHL patients who were rituximab-refractory by standard criteria. Rituximab was administered weeks (wks) 1–4 at 375 mg/m2 IV; IL2 was administered SC 3 times/wk at 14 MIU wks 2–5 and at 10 MIU wks 6–9. Results: Twenty-nine patients are enrolled with 23 evaluable. Treatment was well tolerated. Five responses have been documented: 2 complete and 3 partial; 5 patients had stable disease. The distribution of FcγRIIIa 158 allotypes was skewed, with higher frequency of 158 F/F [11/17 (65%)] and a lower frequency of 158 V/F [3/17 (17.5%)]. All 4 clinical responders evaluated for FcγR genotype expressed the 158F/F polymorphism, which has been associated with a decreased response to rituximab. The distribution of FcγRIIa 131 H/R polymorphism demonstrated similar skewing, with an increased frequency of homozygous 131 H/H [7/17 (42%)] and a decrease in 131 H/R [5/17 (29%)]. All 3 clinical responders evaluated for this polymorphism carried the FcγRIIa 131-R genotype, associated with poor outcome to rituximab. Conclusions: These data support an association of the genetic polymorphisms FcγRIIIa 158F/F and FcγRIIa 131 R/R with prior failure to respond to rituximab. Immunotherapy with IL2+R may achieve a critical threshold to drive ADCC more effectively in patients carrying low affinity IgG FcR allotypes, restoring their response to monoclonal antibody therapy. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration R & D Chiron Corp. Chiron Corp. Chiron Corp. Chiron Corp.
Characteristics and Mode of Growth of a Tissue Culture Strain (EB1) of Human Lymphoblasts From Burkitt's Lymphoma2
Authors: M. A. Epstein, Y. M. Barr
Journal: JNCI Journal of the National Cancer Institute (1965)

Journal Article Characteristics and Mode of Growth of a Tissue Culture Strain (EB1) of Human Lymphoblasts From Burkitt's Lymphoma Get access M. A. Epstein, M. A. Epstein Search for other works by this author on: Oxford Academic PubMed Google Scholar Y. M. Barr Y. M. Barr Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 34, Issue 2, February 1965, Pages 231–240, https://doi.org/10.1093/jnci/34.2.231 Published: 01 February 1965 Article history Received: 29 June 1964 Published: 01 February 1965
Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer
Authors: J. Cuzick, A. Howell
Journal: Journal of Clinical Oncology (2005)

658 Background: It is now clear that aromatase inhibitors (AIs) have a central role to play in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer. The AIs are more effective than tamoxifen and generally have a better side-effect profile. However, uncertainty exists as to whether they should be offered as the initial adjuvant treatment, or whether they are more effective after an initial ‘priming’ period with tamoxifen, where relative benefits appear to be larger. Also, there is confounding between the efficacy of the different AIs and the timing of treatment. Methods: Models are presented which reflect results from published data to compare the use of an AI upfront with sequencing it after varying periods of initial treatment with tamoxifen. We model recurrence rates for the first 10 years of follow-up for a range of efficacy parameters. Results: It is shown that initial or early treatment with an AI always dominates a strategy of using tamoxifen for 5 years initially for a wide range of parameter values. Using current data to estimate hazard ratios suggests that starting with an AI dominates a 2-year initial use of tamoxifen, even though the reduction in hazard ratios after switching may be larger for sequential treatment. This is more evident for estrogen receptor (ER)-positive/progesterone receptor (PgR)-negative patients, than for ER-positive/PgR-positive patients. Prospective clinical trials are needed to determine the optimal time to introduce an AI. Conclusions: This model suggests that using an AI as initial adjuvant treatment is a better option than switching patients to an AI after 2 or more years of tamoxifen. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca, Novartis, Pfizer AstraZeneca, Novartis, Pfizer AstraZeneca
Concurrent chemoradiotherapy (chemoRT) for nasopharyngeal carcinoma (NPC): 10-year experience at a single institute
Authors: D. Yee, H. Lau, J. Siever, P. Brasher, J. Mackinnon, S. Gluck
Journal: Journal of Clinical Oncology (2004)

5573 Background: Radical treatment of NPC consists of radiotherapy (RT) ± chemotherapy. The ideal chemotherapy regimen to be given with RT is unknown. We report our institute's experience with radical treatment of NPC. Methods: Seventy-nine NPC patients were treated radically at the Tom Baker Cancer Centre (TBCC) between 1992–2002. Their charts were reviewed for initial patient characteristics, treatment given, rate of grade 3–4 acute and late toxicities according to the Radiation Therapy Oncology Group (RTOG) scales, failure patterns and causes of death. Data was analyzed using Intercooled Stata 8 (Stata Corporation, College Station, TX). Kaplan Meier estimates of 3-year overall and disease-free survival (OS, DFS) were calculated. Results: The majority of patients (63.3%) had stage III-IVb disease. Mean RT dose to gross disease was 67.9 Gy and mean treatment time was 50.7 days. Patients were treated with one of three different regimens: RT alone (n=18), RT with concurrent carboplatin, 100 mg/m2 weekly X 5 doses (n=45) or RT with concurrent cisplatin, 20 mg/m2 weeks 1 & 5 of RT (n=16). 94.4%, 80.0%, and 81.2% of each group received all prescribed treatments, respectively. With a mean follow-up of 65 months, the 3-year estimate of DFS in each group was 54.4%, 64.4%, and 73.3%, respectively. With a mean follow-up of 88 months, the 3-year estimate of OS in each group was 49.9%, 67.9% and 70.2%, respectively. Maximal rates of RTOG acute grade 3–4 toxicities were 38.9%, 48.9% and 31.3% respectively. Five patients (6.3%) had late grade 3–4 toxicities. There were no treatment-related deaths. 25.3% of patients were hospitalized during treatment and 71.6% lost =< 9.9% of their pre-treatment weight. Most failures were locoregional (57.1%) with a significant proportion being distant (42.9%). The majority of deaths were NPC-related (90.3%). Conclusions: At the TBCC, concurrent chemoRT for NPC confers a trend for improved DFS and OS compared with RT alone. Toxicity rates in NPC patients receiving concurrent chemoRT were acceptable. No significant financial relationships to disclose.
Risk factors for ectopic pregnancy [letter]
Authors: Weiss Ns, Daling
Journal: JAMA (1988)

The authors question the way researchers defined the control group in a case-control study estimating the risk of ectopic pregnancies in current users of intrauterine devices (IUDs).  They contend that a valid result of any case-control study is dependent upon choosing controls that mimic the population at risk.  They argue that including full-term pregnant women who are not typical of the population at risk of ectopic pregnancy overstates the risk (defined as 13.7 times that of nonusers in the questioned study).  In order to obtain a valid result in studies testing for risk of ectopic pregnancy in IUD users researchers should draw their cases and controls from women who are biologically capable of conceiving a child.  They should then ascertain the presence and type of contraceptive use in cases and controls who are sexually active presumed to be fertile and (for controls) not pregnant at the time the cases conceived.  Such studies may measure the risk of IUD use with alternative methods of contraception.  Even though it is assumed that IUD users are at increased risk of ectopic pregnancy than women using other contraceptives IUD users might not be at high risk of ectopic pregnancy when comparing them with fertile women who use no contraceptives.  To test this the authors suggest that the ratio of IUD users to contraceptive nonusers be compared between cases and controls and removing current users of other contraceptives from the analysis.  A number of barriers to accurate assessment of the relative influence of IUD use on the risk of ectopic pregnancy remains however.
<i>In Vitro</i> Effects of the Endocrine Disruptor <i>p,p</i> ’-DDT on Human Follitropin Receptor
Authors: Mathilde Munier, Julie Grouleff, Louis Gourdin, Mathilde Fauchard, Vanessa Chantreau, Daniel Henrion, Régis Coutant, Birgit Schiøtt, Marie Chabbert, Patrice Rodien
Journal: Environmental Health Perspectives (2016)

1-chloro-4-[2,2,2-trichloro-1-(4-chlorophenyl)ethyl]benzene (p,p'-DDT) is a persistent environmental endocrine disruptor (ED). Several studies have shown an association between p,p'-DDT exposure and reproductive abnormalities.To investigate the putative effects of p,p'-DDT on the human follitropin receptor (FSHR) function.We used Chinese hamster ovary (CHO) cells stably expressing human FSHR to investigate the impact of p,p'-DDT on FSHR activity and its interaction with the receptor. At a concentration of 5 μM p,p'-DDT increased the maximum response of the FSHR to follitropin by 32 ± 7.45%. However, 5 μM p,p'-DDT decreased the basal activity and did not influence the maximal response of the closely related LH/hCG receptor to human chorionic gonadotropin (hCG). The potentiating effect of p,p'-DDT was specific for the FSHR. Moreover, in cells that did not express FSHR, p,p'-DDT had no effect on cAMP response. Thus, the potentiating effect of p,p'-DDT was dependent on the FSHR. In addition, p,p'-DDT increased the sensitivity of FSHR to hCG and to a low molecular weight agonist of the FSHR, 3-((5methyl)-2-(4-benzyloxy-phenyl)-5-{[2-[3-ethoxy-4-methoxy-phenyl)-ethylcarbamoyl]-methyl}-4-oxo-thiazolidin-3-yl)-benzamide (16a). Basal activity in response to p,p'-DDT and potentiation of the FSHR response to FSH by p,p'-DDT varied among FSHR mutants with altered transmembrane domains (TMDs), consistent with an effect of p,p'-DDT via TMD binding. This finding was corroborated by the results of simultaneously docking p,p'-DDT and 16a into the FSHR transmembrane bundle.p,p'-DDT acted as a positive allosteric modulator of the FSHR in our experimental model. These findings suggest that G protein-coupled receptors are additional targets of endocrine disruptors.Munier M, Grouleff J, Gourdin L, Fauchard M, Chantreau V, Henrion D, Coutant R, Schiøtt B, Chabbert M, Rodien P. 2016. In vitro effects of the endocrine disruptor p,p'-DDT on human follitropin receptor. Environ Health Perspect 124:991-999; http://dx.doi.org/10.1289/ehp.1510006.
Gastrointestinal stromal tumors (GIST): Evaluation of malignancy and prognosis in 113 cases retrieved from a population based Cancer Registry of Northern Italy
Authors: C. Mucciarini, G. Rossi, F. Bertolini, C. Cirilli, I. Rashid, R. Valli, G. Luppi, G. Trentini, M. Federico
Journal: Journal of Clinical Oncology (2004)

4232 Background: The definition of gastrointestinal stromal tumors (GIST) has evolved over time and its true incidence is still unknown, probably underestimated. We have reviewed 161 cases of soft tissue tumors of the GI diagnosed in the province of Modena between 1988 and 2002 and registered in the Modena Cancer Registry, with the aim of establish the true incidence and the clinical behavior of the disease. Methods: Diagnostic samples were investigated by ICC for CD117 (Dako), PDGFR-A (Santa Cruz) actin, desmin, S100, and CD34. Cases were classified as GIST if resulted KIT+/PDGFR-A- or KIT-/PDGFR-A+.The tumor behavior was assessed on the basis of tumor size and mitotic count, according to the Consensus panel. Results: The diagnosis of GIST was confirmed in 113 cases, 98 KIT+ (87%) and 15 KIT- (13%). The incidence of GIST was of 13 cases per million inhabitants/year. The GIST identified in our population represent 1,1% of all GI cancers diagnosed in the last 15 years. Fifty seven (50%) were men and 56 (50%) women. Median age at diagnosis was 67 years. Sixty four tumors (57%) arose in the stomach. The risk of aggressive behavior was very low, low, intermediate or high in 13%, 12%, 19%, and 55% of cases, respectively. The most frequent symptoms were abdominal pain (37%) and GI bleeding (21%). Twenty one patients (19%) were asymptomatic. Eighty-six patients (76%) underwent radical surgery. After a median follow-up of 46 months (68 months for pts alive) the 5-year survival rate was 53%. At the same interval the survival rate was 75%, 70% and 72% for patients at very low, low and intermediate risk, and 42% for those at high risk (P = 0.0065). The 5-year relapse-free survival rate after radical surgery of primary GIST was 94% for patients at very low, low and intermediate risk, and 43% for patients at high risk (P < 0.0001). Conclusions: GIST represent a rare but well recognizable disease. The risk of aggressive behavior is high in more than 50% of cases. The finding that after radical surgery all relapses but two occurred in patients classified at high risk of aggressive behavior, confirms the clinical usefulness of the Consensus approach. No significant financial relationships to disclose.
Adverse outcome of hip fractures in older schizophrenic patients
Authors: P E Yarden, M G Finkel, C S Raps, J J Girvan
Journal: American Journal of Psychiatry (1989)

The psychiatric and ambulatory course of 21 older chronic schizophrenic patients who sustained hip fractures was studied prospectively, and their walking ability after the fractures was compared to that of 25 nonpsychiatric hip fracture patients. Although the schizophrenic patients were younger when the hip fractures occurred, their recuperation and ambulatory outcome were significantly worse. The psychiatric course was assessed with a standardized rating scale that was administered 6 months and 1 year after the fractures and compared to similar ratings done before the fractures. Significant mental deterioration was found at 6 months after the fractures, with no further changes later.
By 2025 a million more UK people will be living with life threatening conditions, warns royal college
Authors: Abi Rimmer
Journal: BMJ (2015)

One million more people in the United Kingdom will be living with multiple long term, life threatening conditions by 2025, an analysis by the Royal College of General Practitioners has found. This increase will cost general practice up to £1.2bn (€1.6bn; $1.8bn) a year, the college said.

Speaking at the college’s annual conference in Glasgow on Thursday, Maureen Baker, its chair, said that it was paradoxical that most NHS funding was spent on hospital care rather than general practice.

“We need an NHS that’s properly …